Frank A. Damelio
Frank A. Damelio's purchase track record
Frank A. Damelio has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/13/2026 | ZTS | $501K | -0.4% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
HPE Stock Falls 20% Amid AI Financing Concerns. Hewlett Packard Enterprise shares dropped 20% this week, marking its worst weekly performance to date. The decline was driven by growing investor concerns regarding the financing of AI infrastructure, which triggered a broader selloff in hardware stocks like Dell and Super Micro. This sharp drop has pushed the stock toward its support levels, highlighting significant volatility in the AI sector.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal. Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Pfizer Declares 352nd Straight Dividend, Holds Steady Amid Vaccine Selloff. Pfizer announced its 352nd consecutive quarterly dividend, keeping a yield of about 5.4%. The company’s share price has stayed flat even as other vaccine makers like Novavax and Moderna fell. A new approval for the drug Tukysa could alter the company’s outlook, and analysts are watching the upcoming Q3 2026 earnings report for more detail.
Transaction History
| ZTS | ▼ Sell | Gift | 6,650 | $0 | 8/7/2026 | View on chart |
| ZTS | ▲ Buy | Open Market | 6,650 | $501K | 5/13/2026 | View on chart |
| HPE | ▲ Buy | Option Exercise | 14,499 | $348K | 4/1/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 25,112 | $0 | 3/6/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 919 | $0 | 3/6/2026 | View on chart |
| HPE | ▲ Buy | Option Exercise | 14,323 | $231K | 4/2/2025 | View on chart |
| HPE | ▲ Buy | Option Exercise | 17,390 | $0 | 4/10/2024 | View on chart |
| HPE | ▲ Buy | Option Exercise | 3,444 | $0 | 4/5/2023 | View on chart |
| PFE | ▲ Buy | Option Exercise | 127,160 | $3.3M | 2/26/2022 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 34,607 | $1.7M | 2/26/2022 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 59,370 | $3.0M | 2/26/2022 | View on chart |
| PFE | ▲ Buy | Option Exercise | 153,789 | $4.2M | 2/23/2022 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 38,099 | $1.8M | 2/23/2022 | View on chart |
| PFE | ▼ Sell | Tax Withholding | 76,120 | $3.9M | 2/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Goldman Sachs initiates Zoetis coverage with Neutral rating
Goldman Sachs began covering Zoetis with a Neutral rating and a $74 price target. This follows recent guidance cuts that the market initially shrugged off, alongside a new board appointment. The stock currently trades near a key support level, with an RSI of 71.0 indicating strong recent momentum.
Goldman Sachs initiates Zoetis coverage with Neutral rating. Goldman Sachs began covering Zoetis with a Neutral rating and a $74 price target. This follows recent guidance cuts that the market initially shrugged off, alongside a new board appointment. The stock currently trades near a key support level, with an RSI of 71.0 indicating strong recent momentum.